�ݺ�ߣshows by User: Atefkhayat

�ݺ�ߣshows by User: Atefkhayat / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: Atefkhayat / Fri, 03 Jul 2015 18:52:20 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: Atefkhayat Recipe of a Successfull Presentation /slideshow/recipe-of-a-successfull-presentation/50144026 recipeofasuccessfullpresentation-150703185220-lva1-app6891
]]>
]]> Fri, 03 Jul 2015 18:52:20 GMT /slideshow/recipe-of-a-successfull-presentation/50144026 Atefkhayat@slideshare.net(Atefkhayat) Recipe of a Successfull Presentation Atefkhayat <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/recipeofasuccessfullpresentation-150703185220-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds" />

Recipe of a Successfull Presentation from Atef Khayat, MD, MBA

]]> 333 4 https://cdn.slidesharecdn.com/ss_thumbnails/recipeofasuccessfullpresentation-150703185220-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Medicines outlook through 2016 report /Atefkhayat/medicines-outlook-through-2016-report medicinesoutlookthrough2016report-150529115535-lva1-app6892
The future level of global spending on medicines underscores the similar challenges of access and affordability which face those who consume and pay for healthcare around the world. In the developed markets, including the United States and Europe, the current economic downturn will amplify many of the long-term concerns about aging populations afflicted with expensive chronic diseases and the desire by all healthcare stakeholders to control costs. Across countries, similar policies are already being implemented to rein in spending on expensive therapies, increase the use of generics, address pricing directly through price cuts or indirectly via discounts or rebates, and develop a market for biosimilars as a lower-cost alternative to original biologics. Alternatively, the fast growing pharmerging markets will be driven predominantly by economic gains and rising incomes. This rise in incomes, particularly for the lowest earners, coupled with government commitments to support expanded access to basic healthcare services, will make medicines more broadly available and affordable to millions of people. Further, new therapies for a range of diseases affecting both developed and developing world populations are currently, or will soon become, available transforming patient care. Despite this progress, however, significant gaps remain in the drug arsenal. In this report we quantify these factors and examine the spending and usage of medicines globally through 2016. We intend this report to provide a foundation for meaningful discussion about the value, cost and role of medicines in healthcare over the next five years. Our report was developed as a public service without industry or government funding. Michael Kleinrock Director, Research Development IMS Institute for Healthcare Informatics]]>
The future level of global spending on medicines underscores the similar challenges of access and affordability which face those who consume and pay for healthcare around the world. In the developed markets, including the United States and Europe, the current economic downturn will amplify many of the long-term concerns about aging populations afflicted with expensive chronic diseases and the desire by all healthcare stakeholders to control costs. Across countries, similar policies are already being implemented to rein in spending on expensive therapies, increase the use of generics, address pricing directly through price cuts or indirectly via discounts or rebates, and develop a market for biosimilars as a lower-cost alternative to original biologics. Alternatively, the fast growing pharmerging markets will be driven predominantly by economic gains and rising incomes. This rise in incomes, particularly for the lowest earners, coupled with government commitments to support expanded access to basic healthcare services, will make medicines more broadly available and affordable to millions of people. Further, new therapies for a range of diseases affecting both developed and developing world populations are currently, or will soon become, available transforming patient care. Despite this progress, however, significant gaps remain in the drug arsenal. In this report we quantify these factors and examine the spending and usage of medicines globally through 2016. We intend this report to provide a foundation for meaningful discussion about the value, cost and role of medicines in healthcare over the next five years. Our report was developed as a public service without industry or government funding. Michael Kleinrock Director, Research Development IMS Institute for Healthcare Informatics]]> Fri, 29 May 2015 11:55:34 GMT /Atefkhayat/medicines-outlook-through-2016-report Atefkhayat@slideshare.net(Atefkhayat) Medicines outlook through 2016 report Atefkhayat The future level of global spending on medicines underscores the similar challenges of access and affordability which face those who consume and pay for healthcare around the world. In the developed markets, including the United States and Europe, the current economic downturn will amplify many of the long-term concerns about aging populations afflicted with expensive chronic diseases and the desire by all healthcare stakeholders to control costs. Across countries, similar policies are already being implemented to rein in spending on expensive therapies, increase the use of generics, address pricing directly through price cuts or indirectly via discounts or rebates, and develop a market for biosimilars as a lower-cost alternative to original biologics. Alternatively, the fast growing pharmerging markets will be driven predominantly by economic gains and rising incomes. This rise in incomes, particularly for the lowest earners, coupled with government commitments to support expanded access to basic healthcare services, will make medicines more broadly available and affordable to millions of people. Further, new therapies for a range of diseases affecting both developed and developing world populations are currently, or will soon become, available transforming patient care. Despite this progress, however, significant gaps remain in the drug arsenal. In this report we quantify these factors and examine the spending and usage of medicines globally through 2016. We intend this report to provide a foundation for meaningful discussion about the value, cost and role of medicines in healthcare over the next five years. Our report was developed as a public service without industry or government funding. Michael Kleinrock Director, Research Development IMS Institute for Healthcare Informatics <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/medicinesoutlookthrough2016report-150529115535-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds" /> The future level of global spending on medicines underscores the similar challenges of access and affordability which face those who consume and pay for healthcare around the world. In the developed markets, including the United States and Europe, the current economic downturn will amplify many of the long-term concerns about aging populations afflicted with expensive chronic diseases and the desire by all healthcare stakeholders to control costs. Across countries, similar policies are already being implemented to rein in spending on expensive therapies, increase the use of generics, address pricing directly through price cuts or indirectly via discounts or rebates, and develop a market for biosimilars as a lower-cost alternative to original biologics. Alternatively, the fast growing pharmerging markets will be driven predominantly by economic gains and rising incomes. This rise in incomes, particularly for the lowest earners, coupled with government commitments to support expanded access to basic healthcare services, will make medicines more broadly available and affordable to millions of people. Further, new therapies for a range of diseases affecting both developed and developing world populations are currently, or will soon become, available transforming patient care. Despite this progress, however, significant gaps remain in the drug arsenal. In this report we quantify these factors and examine the spending and usage of medicines globally through 2016. We intend this report to provide a foundation for meaningful discussion about the value, cost and role of medicines in healthcare over the next five years. Our report was developed as a public service without industry or government funding. Michael Kleinrock Director, Research Development IMS Institute for Healthcare Informatics

Medicines outlook through 2016 report from Atef Khayat, MD, MBA

]]> 965 6 https://cdn.slidesharecdn.com/ss_thumbnails/medicinesoutlookthrough2016report-150529115535-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Manager on stage /slideshow/manager-on-stage/48673581 manageronstage-150527191925-lva1-app6892
Dear Manager, Remember; YOU are on stage every day, your TEAM is watching you, everything you do, everything you say.]]>
Dear Manager, Remember; YOU are on stage every day, your TEAM is watching you, everything you do, everything you say.]]> Wed, 27 May 2015 19:19:25 GMT /slideshow/manager-on-stage/48673581 Atefkhayat@slideshare.net(Atefkhayat) Manager on stage Atefkhayat Dear Manager, Remember; YOU are on stage every day, your TEAM is watching you, everything you do, everything you say. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/manageronstage-150527191925-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds" /> Dear Manager, Remember; YOU are on stage every day, your TEAM is watching you, everything you do, everything you say.

Manager on stage from Atef Khayat, MD, MBA

]]> 185 1 https://cdn.slidesharecdn.com/ss_thumbnails/manageronstage-150527191925-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Prince Mohammed bin Nayef and Barak Obama shake hand at the White House on Wednesday 13 of May 2015, What is your comment? /slideshow/hand-shake-48646704/48646704 handshake-150527083058-lva1-app6892
Prince Mohammed bin Nayef and Barak Obama shake hand at the White House on Wednesday 13 of May 2015, What is your comment?]]>
Prince Mohammed bin Nayef and Barak Obama shake hand at the White House on Wednesday 13 of May 2015, What is your comment?]]> Wed, 27 May 2015 08:30:58 GMT /slideshow/hand-shake-48646704/48646704 Atefkhayat@slideshare.net(Atefkhayat) Prince Mohammed bin Nayef and Barak Obama shake hand at the White House on Wednesday 13 of May 2015, What is your comment? Atefkhayat Prince Mohammed bin Nayef and Barak Obama shake hand at the White House on Wednesday 13 of May 2015, What is your comment? <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/handshake-150527083058-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds" /> Prince Mohammed bin Nayef and Barak Obama shake hand at the White House on Wednesday 13 of May 2015, What is your comment?

Prince Mohammed bin Nayef and Barak Obama shake hand at the White House on Wednesday 13 of May 2015, What is your comment? from Atef Khayat, MD, MBA

]]> 209 2 https://cdn.slidesharecdn.com/ss_thumbnails/handshake-150527083058-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Swot analysis show /slideshow/swot-analysis-show/5027155 swotanalysisshow-100821174034-phpapp02
]]>
]]> Sat, 21 Aug 2010 17:40:24 GMT /slideshow/swot-analysis-show/5027155 Atefkhayat@slideshare.net(Atefkhayat) Swot analysis show Atefkhayat <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/swotanalysisshow-100821174034-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds" />

Swot analysis show from Atef Khayat, MD, MBA

]]> 8455 5 https://cdn.slidesharecdn.com/ss_thumbnails/swotanalysisshow-100821174034-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 SWOT Analysis /slideshow/swot-analysis-5025958/5025958 swotanalysisshow-12824097476665-phpapp01
I tried in this presentation to cover every thing related to SWOT analysis, but of course this presentation without demonstration, examples, individual and group workshops will not be enough to maestro SWOT analysis. To maximize the benefits for all; kindly do not hesitate to send me your comments. Atef Khayat dr.atefkhayyat@gmail.com +966503935414]]>
I tried in this presentation to cover every thing related to SWOT analysis, but of course this presentation without demonstration, examples, individual and group workshops will not be enough to maestro SWOT analysis. To maximize the benefits for all; kindly do not hesitate to send me your comments. Atef Khayat dr.atefkhayyat@gmail.com +966503935414]]> Sat, 21 Aug 2010 12:01:53 GMT /slideshow/swot-analysis-5025958/5025958 Atefkhayat@slideshare.net(Atefkhayat) SWOT Analysis Atefkhayat I tried in this presentation to cover every thing related to SWOT analysis, but of course this presentation without demonstration, examples, individual and group workshops will not be enough to maestro SWOT analysis. To maximize the benefits for all; kindly do not hesitate to send me your comments. Atef Khayat dr.atefkhayyat@gmail.com +966503935414 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/swotanalysisshow-12824097476665-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds" /> I tried in this presentation to cover every thing related to SWOT analysis, but of course this presentation without demonstration, examples, individual and group workshops will not be enough to maestro SWOT analysis. To maximize the benefits for all; kindly do not hesitate to send me your comments. Atef Khayat dr.atefkhayyat@gmail.com +966503935414

SWOT Analysis from Atef Khayat, MD, MBA

]]> 37411 13 https://cdn.slidesharecdn.com/ss_thumbnails/swotanalysisshow-12824097476665-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-Atefkhayat-48x48.jpg?cb=1567269027 Since I've started my professional career as a medical doctor on 1998; my objective was helping People to cure their illnesses. Now I’m passionate about helping people to Develop themselves to achieve the optimum Performance since I’m Soft Skills & Business Trainer, Recruitment Consultant and HR professional https://cdn.slidesharecdn.com/ss_thumbnails/recipeofasuccessfullpresentation-150703185220-lva1-app6891-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/recipe-of-a-successfull-presentation/50144026 Recipe of a Successful... https://cdn.slidesharecdn.com/ss_thumbnails/medicinesoutlookthrough2016report-150529115535-lva1-app6892-thumbnail.jpg?width=320&height=320&fit=bounds Atefkhayat/medicines-outlook-through-2016-report Medicines outlook thro... https://cdn.slidesharecdn.com/ss_thumbnails/manageronstage-150527191925-lva1-app6892-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/manager-on-stage/48673581 Manager on stage